MedTrace Logo

a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors

NCT06878612 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-06-05

No results posted yet for this study

Summary

This project intends to carry out phase I clinical studies on the basis of the previous work, initially exploring the possible effective dose, evaluating its safety and tolerability, with a view to achieving long-term control of the disease, which is expected to provide more options for the treatment of patients with advanced malignant solid tumors. The development of this project will provide new ideas, strategies and theoretical basis for the research and development of whole tumor cell vaccines; at the same time, it is expected to obtain original new drugs with independent intellectual property rights.

Conditions

  • Polyphenols
  • Cancer Vaccine
  • Advanced Solid Tumor

Interventions

BIOLOGICAL

Polyphenol whole tumor cell vaccine

3 patients enrolled in each dose group, and planned dose groups of 5 x 10\*6, 2 x 10\*7, and 5 x 10\*7 cells/dose. The dosing regimen consisted of 5 doses of basal immunization and subsequent individualized treatment. In the basal immunization, the administration times were D0, D14, D28, D42, and D56. After completion of the 5 doses of basal immunization, the subsequent individualized treatment was decided by the investigator based on the subject's tumor assessment, i.e., 1 vaccination per month for a total of 4 doses.

Sponsors & Collaborators

  • Xingchen Peng

    lead OTHER

Principal Investigators

  • Xingchen Peng, Professor · Department of Biotherapy, West China Hospital, Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-21
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06878612 on ClinicalTrials.gov